Bafna Pharmaceuticals Share Price

Bafna Pharma. Corporate Action

CMP as on 04-Oct-22 14:07

₹ 103.00
0.55 0.54%

Open

₹ 102.40

Turnover (lac)

₹ 2

Prev. Close

₹ 102.45

Day's Vol (shares)

₹ 1,486

Day's Range (₹)

₹ 98.40
₹ 103.05

CMP as on04-Oct-22 15:29

₹ 103.00
3 3%

Open

₹ 103.50

Turnover (lac)

Prev. Close

₹ 100.00

Day's Vol (shares)

₹ 93

Day's Range

₹ 99.40
₹ 103.50

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
AGM 28-Jul-2022 26-May-2022 - -
AGM 28/07/2022 1. AUDITED FINANCIAL RESULTS Approval of audited financial results of the Company for the quarter and year ended 31st March 2022. Please find enclosed the following: 1. Audited financial statements (standalone) for the quarter and year ended 31st March 2022 along with Auditors report for the said period 2. Declaration on Unmodified Opinion in the Auditors Report for Financial Year ended March 31, 2022 2. ANNUAL GENERAL MEETING The 27th Annual General Meeting of the members of the Company is scheduled to be held on Thursday, 28th July 2022 at 12:00 Noon through video conferencing and other audio visual means. 3. To open wholly owned subsidiary of Bafna Pharmaceuticals Limited in Australia. (As Per BSE Announcement dated on 26.05.2022) We hereby inform you that 27th Annual General Meeting of the Company is scheduled to be held on Thursday, 28th July 2022. Further, pursuant to Regulation 42 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Register of Beneficial Owners, Register of Members and Share Transfer Books of the Company shall remain closed from 22nd July 2022 to 28th July 2022 (both days inclusive) for the purpose of Annual General Meeting. (As Per BSE Announcement Dated on 05/07/2022) We wish to inform you that the 27th Annual general meeting of the Company will be held on Thursday 28th July 2022 at 11:00 am through Video-Conferencing. Pursuant to Regulation 34(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Annual Report of the Company for the financial year 2021 - 2022, which has been sent to the members of the Company through electronic mode. The Copy of the report and accounts of the Company for the financial year ended 31st March 2022 together with the Notice are also being uploaded on the Companys website www.bafnapharma.com (As Per BSE Announcement Dated on 06.07.2022) Please be informed that the 27th AGM of the Company was held on 28TH JULY 2022 through Video Conferencing (VC)/ Other Audio Visual Means (OAVM) at 11.00 a.m. IST. In this regard please find attached the summary of the proceedings of the AGM of the Company. The voting results of the 27th Annual General Meeting of the Company along with the Scrutinizer report will be shared shortly. The 27th Annual General Meeting of the Company was concluded at 11.30 A M We request you to take the above information on your record (As Per BSE Announcement dated on 28.07.2022) Bafna Pharmaceuticals Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015 Attached is the scrutinizer report of the AGM held on 28.07.2022 (As per BSE Announcement Dated on 29/07/2022)
Open ZERO Brokerage Demat Account Open Demat Account
  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity